BNP Paribas Financial Markets Takes Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

BNP Paribas Financial Markets purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 100,012 shares of the company's stock, valued at approximately $339,000. BNP Paribas Financial Markets owned about 0.07% of Xeris Biopharma at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. NewEdge Advisors LLC purchased a new position in Xeris Biopharma during the 4th quarter worth approximately $34,000. R Squared Ltd purchased a new position in shares of Xeris Biopharma during the 4th quarter valued at approximately $42,000. Cibc World Markets Corp purchased a new position in shares of Xeris Biopharma during the 4th quarter valued at approximately $44,000. Raymond James Financial Inc. purchased a new position in shares of Xeris Biopharma during the 4th quarter valued at approximately $45,000. Finally, Aquatic Capital Management LLC purchased a new stake in Xeris Biopharma in the 4th quarter worth $50,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Trading Up 5.4%

Shares of Xeris Biopharma stock traded up $0.26 during trading hours on Thursday, hitting $5.04. 1,693,172 shares of the company were exchanged, compared to its average volume of 1,963,633. Xeris Biopharma Holdings, Inc. has a 1 year low of $1.86 and a 1 year high of $6.07. The business has a 50-day moving average of $4.68 and a 200-day moving average of $3.99. The stock has a market capitalization of $788.18 million, a price-to-earnings ratio of -11.20 and a beta of 1.10.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. The company had revenue of $57.80 million for the quarter, compared to analysts' expectations of $57.61 million. As a group, research analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on XERS shares. Jefferies Financial Group reaffirmed a "buy" rating and set a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Wall Street Zen cut shares of Xeris Biopharma from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. HC Wainwright reissued a "buy" rating and set a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Leerink Partners boosted their price target on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research report on Friday, March 7th. Finally, Piper Sandler reissued a "neutral" rating and set a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $6.25.

Insider Transactions at Xeris Biopharma

In other news, insider Beth Hecht sold 40,000 shares of the firm's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the transaction, the insider now owns 1,353,510 shares in the company, valued at $7,349,559.30. This trade represents a 2.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 6.47% of the company's stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.